A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

NCT02788279 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

363

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody
DRUG: Cobimetinib
DRUG: Regorafenib

Sponsor

Hoffmann-La Roche